A syrup is a form of oral cannabis
A product described as THC syrup is a sweet liquid containing tetrahydrocannabinol intended to be swallowed. The liquid format changes the presentation, not the identity of THC as an intoxicating cannabinoid. It belongs to the broader category of ingested cannabis rather than to inhaled exposure.
The term syrup also does not establish pharmaceutical status. Medicines, food products and unregulated preparations can all be liquids; their composition, purpose and regulatory pathway determine which category applies.
Oral effects arrive later
Health Canada explains that the effects of eating or drinking cannabis can begin after thirty minutes to two hours, with full effects taking up to four hours. Effects can last considerably longer than the initial impression suggests, and some residual impairment can persist into the following day.
This delay creates a particular poisoning risk: the absence of an immediate effect can be mistaken for absence of THC activity. The CDC identifies delayed onset as a reason people can ingest excessive amounts. Sweet flavour and drink-like packaging can also make a product resemble ordinary food to children or other household members.
Spain has issued alerts about cannabinoid sweets
AESAN’s alert ES2025/624 concerned HHC and THC in Heavens Haze confectionery from the Czech Republic, following a notification by Valencian health authorities through Spain’s rapid food-information system. It is a documented example of food surveillance responding to cannabinoid products.
That alert concerns specified confectionery, not a measurement of syrup sales across Spain. It shows why presentation as a sweet product does not settle compliance with food rules. ACSA’s September 2026 guidance also states that cannabinoid novel-food authorisation had not yet been granted; a favourable scientific opinion on a particular CBD preparation was not itself marketing permission.
The medical oral solution follows another framework
AEMPS’s 2026 cannabis monograph concerns a standardised THC–CBD oral solution used within Spain’s magistral-medicine framework. Specialist prescribing and hospital-pharmacy preparation, dispensing and monitoring are part of that system.
A retail bottle using the words THC or syrup does not acquire those clinical responsibilities or pharmaceutical standards through its label. The distinction is concrete: an oral format can be shared while the preparation’s legal status, composition and oversight differ substantially.
Sources & further reading
General information, not individual legal or medical advice.